期刊文献+

原发性肝癌肝动脉化疗栓塞术后腹痛的发生规律及影响因素 被引量:32

The regularity of abdominal pain and its influence factors in patients with primary hepatocellular carcinoma after receiving TACE
暂未订购
导出
摘要 目的调查原发性肝癌(PHC)患者行肝动脉化疗栓塞(TACE)术后腹痛的发生规律及影响因素。方法入组121例患者,均为浙江省肿瘤医院介入放射科2012年12月至2013年6月收住的PHC患者。观察患者在TACE术后48 h内腹痛的发生和持续时间、程度及吗啡用量等。结果 121例患者中有96例(96/121,78.5%)在介入术后感到不同程度的腹痛,其中72例(72/121,59.5%)为视觉模拟评分(VAS)4分以上的中重度疼痛。平均吗啡用量为19.7 mg/例次。统计分析发现TACE术后腹痛与年龄(≥60对<60;odd ratio(OR)0.307,P=0.008),术前ECOG评分(2对0~1;OR 0.195,P=0.006),肿瘤至肝包膜距离(>1 cm对≤1 cm;OR 0.296,P=0.007),动脉栓塞时所用化疗药物表柔比星(THP)对其他药物(非THP对THP;OR 0.232,P<0.003 4)。具有上述危险因素1个以上的患者更易发生疼痛。结论腹痛是TACE术后的高频事件,更年轻者、更好的ECOG评分、距肝包膜更近的肿瘤位置以及使用THP混合碘油栓塞者是腹痛发生的独立影响因素。因此对于腹痛的中高危患者,在术前至术后12 h内常规使用止痛药物预防疼痛发生是有必要的。 Objective To investigate the regularity of abdominal pain and its influence factors in patients with primary hepatic carcinoma (PHC) after receiving transcatheter arterial chemoembolization (TACE). Methods A total of 121 patients with PHC were enrolled in this study. All patients were admitted to the Department of Interventional Radiology of Zhejiang Provincial Cancer Hospital from December 2012 to June 2013, and all patients were suffered from PHC. The occurrence, duration and severity of the abdominal pain as well as the used dosage of morphine within 48 hours after TACE were documented. The results were statistically analyzed. Results A total of 96 patients (96/121, 78.5% ) complained of different degrees of abdominal pain after interventional therapy, and 72 patients (72/121, 59.5% ) showed moderate to severe pain, with the VAS score being more than 4 points. The average dosage of morphine used each time for one patient was 19.7 mg. Statistical analysis indicated that these patients were more prone to develop abdominal pain after TACE if they carried more than one of the following risk factors: age ≥60 years (when compared with patients 〈60 years, OR :0.307, P=0.008), preoperative ECOG score 〉2 (when compared with a ECOG score of 0-1, OR:0.195, P=0.006), the distance between tumor and liver capsule 〉1 cm (when compared with the distance ≤1 cm, 0R:0.296, P=0.007), the use of THP in performing chemoembolization (when compared with other chemotherapeutic drugs, OR :0.232, P〈0.003 4). Conclusion After TACE abdominal pain is a high-frequency event. The independent factors affecting the occurrence of abdominal pain are age〈 60 years, preoperative ECOG score 〉2, tumor located close to liver capsule, and the use of THP-lipiodol mixture as embolic agent. Therefore, for patients carrying moderate-high risk of abdominal pain, routine use of analgesics before TACE as well as within 12 hours after TACE to prevent the occurrence of abdominal pain is quite necessary.
作者 罗君 邵国良 郑家平 陈玉堂 姚征 曾晖 郝伟远 LUG Jun SHAO Guoliang ZHENG Jiaping CHEN Yutang YAO Zheng ZENG Hui HAO Weiyuan(Department of Interventional Radiology, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province 310022, China)
出处 《介入放射学杂志》 CSCD 北大核心 2017年第7期613-617,共5页 Journal of Interventional Radiology
基金 浙江省卫生高层次创新人才培养工程基金(浙卫发2012-241号)
关键词 肝动脉化疗栓塞术(TACE) 肝细胞肝癌 腹痛 危险因素 hepatic arterial chemoembolization hepatocellular carcinoma abdominal pain risk factor
  • 相关文献

参考文献3

二级参考文献47

  • 1原发性肝癌的临床诊断与分期标准[J].肝脏,2004,9(S1):67-68. 被引量:53
  • 2Xiao-Dong Lin,Li-Wu Lin.Local injection therapy for hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2006,5(1):16-21. 被引量:4
  • 3Yun-Chung Cheung,Sheung-Fat Ko,Shu-Hang Ng,Siu-Cheung Chan.Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(18):2792-2795. 被引量:5
  • 4王江云,李彦豪,卢伟,陈勇,韦传军.肝癌TACE治疗后发热影响因素分析[J].南方医科大学学报,2007,27(9):1417-1418. 被引量:18
  • 5许秀芳,李晓蓉,刘玉金.肿瘤介入护理学[M].北京:科学出版社,2011:32.
  • 6Sutherland LM,Williams JA,Padbury RT,Gotley DC,Stokes B,Maddern GJ.Radiofrequency ablation of liver tu-mors:a systematic review. Archives of Surgery . 2006
  • 7Liu K,Lu J,Tan W.[Portal vein supply and embolization therapy for hepatocellular carcinoma]. Chinese Medical Journal . 1995
  • 8Yamada R,Nakatsuka H,Nakamura K,Sato M,Itami M,Kobayashi N,Minakuchi K,Onoyama T,Kanno T,Monna T,Yamamoto S.Hepatic artery embolization in32patients with unresectable hepatoma. Osaka City Medical Journal . 1980
  • 9Vogl TJ,Naguib NN,Nour-Eldin NE,Rao P,Emami AH,Zangos S,Nabil M,Abdelkader A.Review on transarterial chemoembolization in hepatocellular carcinoma:palliative,combined,neoadjuvant,bridging,and symptomatic indica-tions. European Journal of Radiology . 2009
  • 10Yu SC,Hui JW,Hui EP,Mo F,Lee PS,Wong J,Lee KF,Lai PB,Yeo W.Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcino-ma:a case-controlled comparison of transarterial ethanol abla-tion with lipiodol-ethanol mixture versus transcatheter arterial chemoemboliza. Journal of Vascular and Interventional Radiology . 2009

共引文献519

同被引文献304

引证文献32

二级引证文献285

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部